Intrasite 15 gm

INTRASITE Gel 15 g is a sterile, amorphous hydrogel supplied in a 15 g Applipak tube designed for topical wound management. Formulated primarily from a hydrophilic polymer base (high-water content hydrogel), INTRASITE Gel gently rehydrates necrotic tissue, facilitates autolytic debridement, helps to loosen slough, and creates an optimal moist environment to support wound healing and promote granulation and epithelialisation. It is intended for use across a broad range of wound types — from superficial cuts and minor burns to chronic leg ulcers, pressure injuries and diabetic foot ulcers — under the guidance of a healthcare professional.

Key Features

How INTRASITE Gel Works

INTRASITE Gel works by reintroducing and maintaining moisture at the wound surface. Its amorphous hydrogel matrix:

• Rehydrates necrotic tissue and slough, which softens and loosens devitalised material and supports the body’s natural (autolytic) debridement processes.
• Absorbs and locks in small amounts of exudate, while maintaining a moist wound bed that promotes cell migration and granulation.
• Is non-adherent to viable tissue, reducing trauma and pain at dressing changes and preserving fragile granulating tissue.

These combined actions create a wound environment that is conducive to progressive healing, particularly in wounds where desiccation or adherent necrotic tissue is impeding recovery. INTRASITE Gel is compatible with secondary dressings (films, foams or gauze) selected according to wound exudate levels and clinical needs.

Indications / Uses

INTRASITE Gel is indicated for a wide range of wound types where moist wound management or autolytic debridement is appropriate, including:

• Pressure ulcers and pressure injuries (all stages where autolytic debridement is indicated).
• Venous leg ulcers and other chronic leg ulcers.
• Diabetic foot ulcers and other neuropathic/vascular wounds (when used under clinical supervision).
• Surgical wounds, superficial lacerations, skin tears and minor burns.
• Malignant or fungating wounds (with specialist oversight).
• Granulating cavity wounds and wounds requiring gentle moisturisation to support epithelialisation.

Clinicians may also use INTRASITE Gel as part of post-operative wound care or to manage wounds with dry necrosis or adherent slough that require moist rehydration before further debridement or definitive closure. Use on infected wounds should be guided by clinical judgement and, where appropriate, in conjunction with antimicrobial strategies.

Dosage & How to Use

General approach — follow local protocols and the product insert. The steps below reflect common, evidence-based practice:

1. Prepare the wound: clean and irrigate the wound with normal saline or an approved wound cleanser. Gently pat the peri-wound skin dry while keeping the wound bed moist.
2. Apply a skin barrier to the surrounding intact skin if there is a risk of maceration from exudate or gel run-off.
3. Apply the gel: using a gloved hand or sterile applicator, place enough gel to lightly cover the wound bed—typically a thin layer to fill shallow defects or a small amount into cavities. Avoid overfilling; gel should not be packed into tight, narrow tunnels where removal would be difficult.
4. Cover with an appropriate secondary dressing: choose a secondary dressing according to exudate level (semi-permeable film, foam, alginate for higher exudate, etc.). Replace secondary dressings per wound status and local policy.
5. Frequency of dressing changes: depends on wound condition and exudate — many clinicians reassess every 24–72 hours initially; granular, low-exudate wounds may require less frequent changes. Follow the treating clinician’s advice.

Practical note: Avoid absorptive primary dressings directly over gel unless intended; the gel can be taken up by strong absorptive dressings and lose effectiveness.

Expected Benefits

• Facilitates autolytic debridement without aggressive mechanical scraping, preserving viable tissue and reducing pain during dressing changes.
• Promotes a moist wound environment, which supports cell migration, angiogenesis and epithelialisation — central processes in wound healing.
• Reduces trauma at dressing changes because the gel is non-adherent and gentle on new granulation tissue.
• Versatile across wound stages: useful in early debridement of necrotic wounds and later to maintain moisture in granulating and epithelialising wounds.
• Simple, easy to apply delivery (Applipak tube) for controlled dispensing and minimal contamination risk.

Clinical response varies by wound type, comorbidities (e.g., diabetes, vascular disease), and adherence to a comprehensive wound care plan (offloading, infection control, nutrition).

Side Effects & Precautions

Common / expected local effects

• Mild peri-wound maceration if excessive gel or inappropriate secondary dressing choice allows pooling of moisture. Using a skin barrier and appropriate secondary dressing reduces this risk.

Less common / important cautions

• Not suitable for heavily exuding wounds where a more absorbent primary dressing is required; the gel alone cannot manage large volumes of exudate.
• Caution in narrow, deep fistulas or sinuses — gel may be difficult to remove from tight tracts. Avoid deep packing where retrieval is problematic.
• Sensitivity / allergy: discontinue if local hypersensitivity to product components is suspected.
• Infected wounds: while INTRASITE Gel can be used under supervision on infected wounds, overt infection requires appropriate systemic or topical antimicrobial therapy as directed by a clinician. Do not rely on gel alone to treat uncontrolled infection.

Always follow local infection control and wound-care protocols, and escalate to specialist care if the wound deteriorates, shows increasing necrosis, malodour, spreading cellulitis, or systemic signs.

Interactions & Important Clinical Notes

• Secondary dressings matter: choose a secondary dressing that matches exudate — film or low-adherent dressings for low exudate; foams or alginates when exudate increases. Using a highly absorptive secondary dressing can remove gel prematurely; coordinate dressing strategy.
• Use with topical antimicrobials: if infection is present, topical antimicrobial products or systemic antibiotics may be needed. Consult clinical guidance.
• Monitoring: reassess wound progress regularly; lack of improvement or worsening requires re-evaluation of diagnosis, offloading, vascular supply, glycaemic control and infection status.

Storage & Handling

Store INTRASITE Gel as indicated on the pack—typically at controlled room temperature, protected from extreme heat and direct sunlight. Keep the tube cap closed to minimise contamination. Use aseptic technique when applying and discard any unused portion if sterility is compromised.

Practical Tips & Realistic Expectations

• Expect staged progress: necrotic or sloughy wounds may require several applications and reassessment before healthy granulation is established.
• Address underlying factors: optimal outcomes depend on treating contributing causes — pressure redistribution, vascular assessment, glycaemic control, nutrition and infection control.
• Patient comfort: non-adherent removal reduces dressing pain; however, some transient exudate increase may be seen early as debris softens. This is often part of the debridement process.
• Documentation: record wound size, appearance, exudate, odour and pain at each dressing change to track response.

Conclusion

INTRASITE Gel 15 g is a versatile, clinician-favourite amorphous hydrogel dressing that supports moist wound healing and autolytic debridement across a broad range of wound types. When integrated into a comprehensive wound-care strategy and used with appropriate secondary dressings, it offers gentle, effective rehydration of necrotic tissue and a non-traumatic approach to progressing wounds through granulation and epithelialisation. Use under healthcare supervision ensures safe application, correct dressing selection, and timely escalation when complications arise.

References

• https://pmc.ncbi.nlm.nih.gov/articles/PMC5793452/
• https://pubmed.ncbi.nlm.nih.gov/39219040/

FAQ’s